Ono Pharmaceutical (OTCMKTS:OPHLF) Sees Large Volume Increase - Should You Buy?

Key Points

• Ono Pharmaceutical experienced a significant increase in trading volume, with 29,365 shares traded on Wednesday, marking a 329% rise from the previous session.
• The company reported a quarter earnings per share of $0.26, which was below the consensus estimate of $0.34, despite achieving revenues of $886.27 million, exceeding expectations of $827.29 million.
• Ono has a market cap of $4.86 billion and a low beta of 0.19, indicating lower volatility compared to the overall market.

Ono Pharmaceutical Co. (OTCMKTS:OPHLF - Get Free Report) saw an uptick in trading volume on Wednesday . 29,365 shares were traded during trading, an increase of 329% from the previous session's volume of 6,838 shares.The stock last traded at $10.35 and had previously closed at $10.27.

Ono Pharmaceutical Stock Up 0.8%

The stock has a market cap of $4.86 billion, a PE ratio of 16.69 and a beta of 0.19. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.99 and a quick ratio of 2.44. The business has a fifty day moving average of $11.42 and a 200-day moving average of $11.03.

Ono Pharmaceutical (OTCMKTS:OPHLF - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported $0.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.34 by ($0.08). The firm had revenue of $886.27 million for the quarter, compared to analysts' expectations of $827.29 million. Ono Pharmaceutical had a return on equity of 5.47% and a net margin of 8.75%.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.